Status:
COMPLETED
Fexofenadine in Pruritic Skin Disease
Lead Sponsor:
Handok Inc.
Conditions:
Pruritus
Eligibility:
All Genders
12-70 years
Phase:
PHASE4
Brief Summary
Primary objective: * To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Se...
Eligibility Criteria
Inclusion
- The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
- Main criteria are listed hereafter:
- All patients diagnosed with atopic dermatitis, contact dermatitis
Exclusion
- Other skin disease except atopic dermatitis, contact dermatitis.
- Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening day.
- Pruritus localized only head and face
- Subjects with severe hepatic, renal, heart dysfunction.
- Subjects with history of alcohol and drug abuse.
- Pregnant and lactating women.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
435 Patients enrolled
Trial Details
Trial ID
NCT00261079
Start Date
April 1 2005
End Date
October 1 2006
Last Update
November 7 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Handok
Seoul, South Korea